Trial · NCT03240133
Adverse events128
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
61 to 80 of 128
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Nausea | Gastrointestinal disorders | Part1: Berotralstat 750 mg | 2 | 33 | 2 |
| other | Nausea | Gastrointestinal disorders | Part 2: Berotralstat 500 mg | 2 | 14 | 2 |
| other | Nausea | Gastrointestinal disorders | Part 3: Berotralstat 250 mg | 1 | 11 | 2 |
| other | Nausea | Gastrointestinal disorders | Parts 1, 2 and 3: Placebo | 0 | 53 | 0 |
| other | Epigastric discomfort | Gastrointestinal disorders | Part1: Berotralstat 750 mg | 0 | 33 | 0 |
| other | Epigastric discomfort | Gastrointestinal disorders | Part 2: Berotralstat 500 mg | 1 | 14 | 1 |
| other | Epigastric discomfort | Gastrointestinal disorders | Part 3: Berotralstat 250 mg | 0 | 11 | 0 |
| other | Epigastric discomfort | Gastrointestinal disorders | Parts 1, 2 and 3: Placebo | 0 | 53 | 0 |
| other | Gastrooesophageal reflux disease | Gastrointestinal disorders | Part1: Berotralstat 750 mg | 0 | 33 | 0 |
| other | Gastrooesophageal reflux disease | Gastrointestinal disorders | Part 2: Berotralstat 500 mg | 1 | 14 | 1 |
| other | Gastrooesophageal reflux disease | Gastrointestinal disorders | Part 3: Berotralstat 250 mg | 0 | 11 | 0 |
| other | Gastrooesophageal reflux disease | Gastrointestinal disorders | Parts 1, 2 and 3: Placebo | 0 | 53 | 0 |
| other | Vomiting | Gastrointestinal disorders | Part1: Berotralstat 750 mg | 1 | 33 | 1 |
| other | Vomiting | Gastrointestinal disorders | Part 2: Berotralstat 500 mg | 1 | 14 | 1 |
| other | Vomiting | Gastrointestinal disorders | Part 3: Berotralstat 250 mg | 0 | 11 | 0 |
| other | Vomiting | Gastrointestinal disorders | Parts 1, 2 and 3: Placebo | 0 | 53 | 0 |
| other | Nasopharyngitis | Infections and infestations | Part1: Berotralstat 750 mg | 4 | 33 | 4 |
| other | Nasopharyngitis | Infections and infestations | Part 2: Berotralstat 500 mg | 1 | 14 | 1 |
| other | Nasopharyngitis | Infections and infestations | Part 3: Berotralstat 250 mg | 0 | 11 | 0 |
| other | Nasopharyngitis | Infections and infestations | Parts 1, 2 and 3: Placebo | 1 | 53 | 1 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03240133/events?page=4